Egetis Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-342.5	-343.6	-326.9	-193.8	-104.5
Depreciation & Amortization	-	3.5	3.6	2.7	2.5
Stock-Based Compensation	-	14.7	8	8.8	1.2
Other Operating Activities	49.1	8.9	6	-2.1	-1.1
Change in Accounts Receivable	-8.6	13.4	-22.9	-10.7	3.1
Change in Other Net Operating Assets	35	75.2	53.8	21.6	-31.3
Operating Cash Flow	-267	-227.9	-278.4	-173.5	-130.1
Capital Expenditures	-1.5	-	-	-	-0.2
Cash Acquisitions	-1.3	-1.2	-	-1.7	-5
Investment in Securities	-	-	-	-	-0.8
Investing Cash Flow	-2.8	-1.2	-	-1.7	-6
Long-Term Debt Issued	-	-	108.8	-	-
Long-Term Debt Repaid	-31.9	-10.2	-5.6	-9.1	-8.9
Net Debt Issued (Repaid)	-31.9	-10.2	103.2	-9.1	-8.9
Issuance of Common Stock	183.2	301.5	381.9	177.4	-
Repurchase of Common Stock	-	-1.5	-	-	-
Other Financing Activities	-11.3	-18.9	-26.2	-12.6	-
Financing Cash Flow	140	270.9	458.9	155.7	-8.9
Foreign Exchange Rate Adjustments	-5.4	5.8	-4.8	3.2	1.1
Net Cash Flow	-135.2	47.6	175.7	-16.3	-143.9
Free Cash Flow	-268.5	-227.9	-278.4	-173.5	-130.3
Free Cash Flow Margin	-430.29%	-494.36%	-483.33%	-767.70%	-341.10%
Free Cash Flow Per Share	-0.73	-0.73	-1.07	-0.89	-0.72
Cash Interest Paid	-	8.5	4.1	0.1	-
Cash Income Tax Paid	0.5	0.3	0.1	-	-
Levered Free Cash Flow	-185.69	-105.33	-159.79	-112.39	-90.55
Unlevered Free Cash Flow	-171.5	-94.33	-157.16	-112.33	-90.43
Change in Working Capital	26.4	88.6	30.9	10.9	-28.2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.